key: cord-0887843-56w1f8i0 authors: Kolb, Martin; Dinh-Xuan, Anh Tuan; Brochard, Laurent title: Guideline directed management of COVID-19: Do's and Dont's date: 2021-03-25 journal: Eur Respir J DOI: 10.1183/13993003.00753-2021 sha: 9b7354033f1e8f92261ad9e69ad47995f96aeed1 doc_id: 887843 cord_uid: 56w1f8i0 The COVID-19 pandemic continues to dominate our daily lives. The “second wave” seems to slow down in most regions around the globe. Whether or not a major third wave of infections, hospitalisations and death will occur depends on the effect of public health measures and the efficacy and speed of vaccination programs. Unfortunately, we have to expect that COVID-19 will persist as a major challenge for the delivery of medical care for a long while to go. Despite all efforts, a significant number of patients, in particular the elderly and those with risk factors, will get ill from this disease and some will eventually require hospitalisation. The COVID-19 pandemic continues to dominate our daily lives. The "second wave" seems to slow down in most regions around the globe. Whether or not a major third wave of infections, hospitalizations and death will occur depends on the effect of public health measures and the efficacy and speed of vaccination programs. Unfortunately, we have to expect that COVID-19 will persist as a major challenge for the delivery of medical care for a long while to go. Despite all efforts, a significant number of patients, in particular the elderly and those with risk factors, will get ill from this disease and some will eventually require hospitalization. During the early stages of the pandemic, empirical use of antiviral and anti-inflammatory drugs such as hydroxychloroquine, lopinavir-ritonavir, remdesivir and monoclonal antibodies was widespread [1, 2] . Randomized clinical trials have been conducted at an unprecedented rate to generate evidence for specific interventions [1, 3] . From the second half of 2020, many of these trials were readily available in the medical literature, often as a non-reviewed article on pre-print servers, before they got processed fast track in the peer-reviewed journals. Results were often mixed and inconclusive, due to issues related to study design, study size and follow up period. If in the beginning of the pandemic it is understandable that clinical decision making was driven by sub-optimal study reports to cope with an emergency situation, it is now time to create better developed guidance documents to control a disease that will not be easily eradicated. As COVID-19 is here to stay, from now on clinicians will need the best possible recommendations for managing COVID-19 patients, based on robust data and studies, assessed as a whole with applying appropriate methodology. In this issue of the ERJ, Chalmers et al publish the first comprehensive evidence-based recommendations related to the management of hospitalized adults with COVID-19 using GRADE methodology [4] . This guideline was developed and endorsed by the European One of the issues associated with the unprecedented speed with which new evidence for the management of COVID-19 is accumulating is that writing guidelines and updating them are both lengthy processes. This makes guidelines running the risk of being "out of date" the day they are published with such a fast-evolving crisis such as the COVID-19 pandemic . Consequently, the present document represents the first ERS Guideline on this topic and is intended to be continuously updated as a "living guideline". The panel members are committed to keep up with continuous literature searches and updated grading and recommendations as new evidence emerges and the ERS intends to publish these as rapid guideline updates on specific topics in one of its journals, namely the ERJ, the ERJ Open Research or the ERR. While timely and invaluable, the guideline did not cover the management of COVID-19 in the community, which remains an area of urgent need. In addition, management of COVID-19 in children is not addressed. Further future needs are in the development of guidelines for longer term management, follow-up of patients who recovered from COVID-19, and COVID vaccines. The ERS has already formed working groups to address some of these important questions. In addition, the topic of ventilatory support is limited to COVID-19 patients with acute hypoxaemic respiratory failure without an immediate indication for invasive mechanical ventilation. The panel conditionally suggested HFNC or non-invasive CPAP delivered through either a helmet or a face-mask for these patients. In order to understand the dilemma, it is important to consider some differences in lung inj ury related to severe COVID-19 and how it is different to the typical ARDS. The initial descriptions of CARDS have mentioned the presence of at least two phenotypes based mostly on lung elastance and the atypical presentation of patients having relatively preserved lung mechanics (good, or low, elastance) but still very significant shunting and hypoxemia [6] . This is somewhat unusual in ARDS, where usually the sickest patients, i.e. those with the lowest oxygenation level, are also those who have the worst lung mechanics and the smaller aerated lung. Therefore, the pathophysiology of "classical" ARDS is usually rather consistent across the different types of abnormalities (gas exchange, mechanics, dead space, reduced lung volumes) as well as for the risk of ventilator induced lung injury (VILI). This apparent dissociation for some CARDS patients suggests a different mechanism for shunt. The autopsy findings described in CARDS patients could potentially offer an anatomical-pathological explanation for these findings, with chaotic aspect of the capillary vascularization (intussusceptive angiogenesis) in addition to the presence of microthrombi [7, 8] . Although the use of a classical lung protective strategy in CARDS is universally recommended [9] , the tolerance of slightly higher tidal volumes (as a way to facilitate the tolerance) has also been proposed in CARDS [5] and is supported by recent analyses in patients with "classical" ARDS when they have low elastance values [10] . Another striking aspect of the presentation of some patients with CARDS is the relatively good tolerance of hypoxemia, called silent hypoxemia [11] also frequently referred to as happy hypoxemia. Although the variability to air hunger and dyspnea in response to hypoxemia is well known and mitigated by different factors often present in COVID-19 patients (age, diabetes, etc) many patients seem to fall in this category with COVID-19 [12] . ACE-2 receptors which bind with the virus spike proteins are present in the chemosensitive carotid bodies and whether their involvement explain a blunted response is unknown. This characteristic raised an important question about the indication for intubation. Mechanical ventilation is primarily indicated to support and reduce the work of breathing, and a dissociation between oxygenation and work of breathing in some of these patients prompted some physicians to recommend waiting until clinical signs of high work of breathing are present before deciding for intubation, even in conditions of severe hypoxemia [12] . This is unusual in ARDS again, because severe hypoxemia is usually associated with poor lung mechanics, high work of breathing and dyspnea. Therefore, techniques to improve oxygenation have become an important part of the management of CARDS including awake self-proning [13] and, as just recommended in the ERS COVID-19 guideline, use of high-flow nasal cannula [4, 14] , which has also the potential to reduce the work of breathing. Several reports have shown that, compared to the management provided in conditions of surge at the beginning of the pandemic, it was possible to reduce the use of invasive mechanical ventilation, a finding clearly observed over time across the duration of the pandemic. Matched cohort studies suggested that a less frequent use of invasive mechanical ventilation was not associated with deleterious effects on survival [14] and in a very large cohort study in the UK, after careful multiple adjustments, less invasive ventilation was associated with a lower mortality [15] . Another debate has concerned the use of PEEP and the recruitability of the lungs of these patients. Recommendations have varied between high PEEP (initially) and low PEEP -FiO 2 tables. As for classical ARDS, however, an individual titration seems desirable since various degrees of lung recruitability have been described both in classical ARDS and in CARDS [16, 17] . One ongoing trial is testing an individualized approach compared to the use of PEEP-FiO2 tables (NCT03963622). Other aspects discussed have concerned the monitoring of the dead space or one of its surrogate (e.g., the ventilatory ratio) which elevation could raise the suspicion of micro or macrovascular thrombi; but the evidence there is very weak and cannot replace other markers. The need to monitor and control the respiratory drive under assisted ventilation after the initial phase has also been emphasized to potentially avoid mechanisms of self-inflicted lung injury [18] . A small study suggested that patients who present a relapse of the initial respiratory failure can be predicted by the presence of a high respiratory drive [19] . Management of sedation has been regularly reported to be complex in this context. All these factors illustrate the difficulty to manage these patients under mechanical ventilation, who, in the most severe forms, may require extracorporeal membrane oxygenation. Indications for ECMO are relatively limited and some series have reported relatively high rates of complications [20] . Much has been learned about the pathogenesis, epidemiology and clinical management of COVID-19 in the last year. We are not aware of any other medical condition that would have ever had such a "high speed" dynamic in the emergence of medical knowledge as reflected in the unprecedented exponential rise in scientific publications during the last 14 months . Despite all the imperfections in the system and the hardship and suffering the pandemic has caused, COVID-19 has also shown how creative and productive humans can be if they work together. Of course, nothing is fast enough when it is about survival of an individual or a society. But the new and first methodologically sound COVID-19 treatment guideline for hospitalized patients is an important step into the future. The ERS COVID-19 guideline teaches health care providers about many of the "do's and the dont's" and it aims to add continuous evidence based advice as new literature emerges. The guideline panel deserves our gratitude for such an enormous and laudable effort. Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval Compassionate drug (mis)use during pandemics: lessons for COVID-19 from COVID-19 Clinical Trials: Unravelling a Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline Management of COVID-19 Respiratory Distress COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? Effect of Lowering Tidal Volume on Mortality in ARDS Varies with Respiratory System Elastance Silent hypoxaemia in COVID-19 patients Why COVID-19 Silent Hypoxemia Is Baffling to Physicians Is the Prone Position Helpful During Spontaneous Breathing in Patients With COVID-19? High-Flow Nasal Cannula in Critically III Patients with Severe COVID-19 Trends in Intensive Care for Patients with COVID-19 in England, Wales, and Northern Ireland Lung Recruitability in COVID-19-associated Acute Respiratory Distress Syndrome: A Single-Center Observational Study Mechanical Ventilation to Minimize Progression of Lung Injury in Acute Respiratory Failure High Respiratory Drive and Excessive Respiratory Efforts Predict Relapse of Respiratory Failure in Critically Ill Patients with COVID-19 Extracorporeal Membrane Oxygenation for Critically Ill Patients with COVID-19-related Acute Respiratory Distress Syndrome: Worth the Effort?